Strengths and prices
| Strength | Price per vial | Availability | Batch | |
|---|---|---|---|---|
| 10 mg | $21.00 | In stock | XA-2607-0021 |
Every vial carries its batch code and a QR that opens the certificate of analysis for that exact batch. No account is needed to read one.
What it is
Semax is a synthetic heptapeptide: the ACTH fragment 4-7 (Met-Glu-His-Phe) extended by Pro-Gly-Pro. It has no hormonal activity of ACTH.
Identity
| Type | Synthetic peptide, 7 amino acids |
|---|---|
| Sequence | Met-Glu-His-Phe-Pro-Gly-Pro |
| Molecular formula | C37H51N9O10S |
| Molecular weight | 813.9 g/mol |
| CAS number | 80714-61-0 |
| PubChem CID | 9811102 |
Semax is a synthetic linear heptapeptide, Met-Glu-His-Phe-Pro-Gly-Pro: the ACTH(4-7) fragment extended by the tripeptide Pro-Gly-Pro. Molecular formula C37H51N9O10S, molecular weight 813.9 g/mol (PubChem CID 9811102, CAS 80714-61-0). It has a free N-terminus and C-terminus and no cysteine. The methionine thioether can oxidize to the sulfoxide, which appears as a separate peak on HPLC and is one reason purity is reported per batch. It is a white, water-soluble lyophilized powder, supplied in a sealed vial.
What the published research covers
Most of the published work is Russian, in rodent models and in clinical studies there. It is a registered medicine in Russia.
Semax was designed in the 1980s and 1990s at the Institute of Molecular Genetics of the Russian Academy of Sciences. Its designers took the ACTH fragment 4-7, Met-Glu-His-Phe, which carries the behavioral but not the hormonal activity of ACTH, and added Pro-Gly-Pro at the C-terminus to slow breakdown by peptidases. It has been a registered medicine in Russia since the 1990s and is not approved elsewhere.
The animal work is almost all in rats and mice. A 2006 study reported that treated rats had a 1.4-fold rise in hippocampal BDNF protein and a 1.6-fold rise in phosphorylation of its receptor trkB, with better performance in a conditioned-avoidance task (Dolotov, 2006). A 2005 study measured monoamines and reported a large rise in a striatal serotonin metabolite and potentiation of amphetamine-induced dopamine release and locomotion (Eremin, 2005). Since 2014 a Moscow group has published a series of transcriptome studies in a rat model of focal cerebral ischemia, reporting that the peptide shifts the expression of immune and neurosignaling genes back toward the pattern seen in uninjured brain (Filippenkov, 2024). Human reports are Russian clinical studies in ischemic stroke, published mainly in Russian-language journals: a 1997 clinical and electrophysiological study (Gusev, 1997) and a 2018 report on 110 patients that recorded plasma BDNF and functional recovery scales (Gusev, 2018).
Nearly all of this work comes from one country and from overlapping groups, with few independent English-language replications. Its receptor target is still debated, since it does not act as a classical melanocortin receptor agonist. The Russian clinical reports do not follow the design standards of a registration trial.
Regulatory status
Registered in Russia. Not approved by the FDA for any use. Supplied for laboratory research only.
Testing and documentation
Identity is confirmed by mass spectrometry and purity by HPLC. The certificate of analysis for the batch is reachable from the code on the vial.
Questions laboratories ask
- What strengths is Semax offered in?
- Vials of 5 mg and 10 mg, as listed on the product page. The amount is on the vial label and on the certificate of analysis for the batch.
- Is this the medicine registered in Russia?
- No. A Russian pharmaceutical product exists under this name; this material is a research peptide of the same sequence, supplied for laboratory research only and not approved by the FDA for any use.
- How is a batch tested?
- By an independent laboratory: identity by mass spectrometry and purity by HPLC. The QR code on the vial opens the certificate of analysis for that exact batch; no account is needed to read it.
- Who can order, and how does it ship?
- Orders are accepted under the Research Use Agreement, reaffirmed with every order. Orders ship from Montana, the next business day when paid by card, to United States addresses only and not to freight forwarders.
References
- Gusev EI et al. (1997). Effectiveness of semax in acute period of hemispheric ischemic stroke (a clinical and electrophysiological study). Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. PubMed 11517472
- Eremin KO et al. (2005). Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents. Neurochemical Research. PubMed 16362768
- Dolotov OV et al. (2006). Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Research. PubMed 16996037
- Gusev EI et al. (2018). The efficacy of semax in the treatment of patients at different stages of ischemic stroke. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. PubMed 29798983
- Filippenkov IB et al. (2024). ACTH-like Peptides Compensate Rat Brain Gene Expression Profile Disrupted by Ischemia a Day After Experimental Stroke. Biomedicines. PubMed 39767736
How it ships
Ordering
Ordering needs an account. A retail account opens as soon as you request it and costs nothing. You pay by card at checkout, or by invoice before the order ships. A wholesale account is reviewed before it opens.
Research use only
This product is a research chemical sold solely for in-vitro laboratory research by qualified persons. It is not a drug, food, supplement or cosmetic, has not been evaluated by the FDA, and must not be administered to any person or animal. Read the full agreement